Back to EUR-Lex homepage

EUR-Lex Access to European Union law

Back to EUR-Lex homepage

This document is an excerpt from the EUR-Lex website

Use quotation marks to search for an "exact phrase". Append an asterisk (*) to a search term to find variations of it (transp*, 32019R*). Use a question mark (?) instead of a single character in your search term to find variations of it (ca?e finds case, cane, care).
Search tips
Need more search options? Use the Advanced search
You are here

Document 62021TN0695

Case T-695/21: Action brought on 28 October 2021 — Alauzun and Others v Commission

OJ C 2, 3.1.2022, p. 45–45 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

Date of document:
28/10/2021
Date lodged:
28/10/2021
Author:
General Court
Form:
Judicial information
Authentic language:
French
Type of procedure:
Action for annulment
Link
Select all documents mentioning this document
Instruments cited in case law:
Link

3.1.2022   

EN

Official Journal of the European Union

C 2/45

Action brought on 28 October 2021 — Alauzun and Others v Commission

(Case T-695/21)

(2022/C 2/62)

Language of the case: French

Parties

Applicants: Virginie Alauzun (Saint Cannat, France) and 774 other applicants (represented by: F. Di Vizio, lawyer)

Defendant: European Commission

Form of order sought

The applicants claim that the Court should:

—

declare that the European Commission (EC) unlawfully failed to include carcinogenicity and genotoxicity testing in the preclinical phase for the mRNA-technology vaccines;

—

order the European Commission to include carcinogenicity and genotoxicity testing in the preclinical phase for mRNA-technology vaccines not yet authorised under the EMA procedure;

—

order the European Commission to include carcinogenicity and genotoxicity testing in the pharmacovigilance phase for mRNA-technology vaccines already authorised under the EMA procedure;

—

request the Commission to disclose the following information:

—

the clear legislative basis as to why the testing at issue was not included in the preclinical and pharmacovigilance testing phases;

—

the regulation setting out the mandatory checks required for the authorisation of mRNA-technology vaccines.

—

order the European Commission to pay all the costs of the applicants.

Pleas in law and main arguments

In support of the action, the applicants allege an infringement of EU law and a failure to act on the part of the Commission. The applicants submit in that regard that the Commission did not comply with its obligation arising under Article 168 TFEU to guarantee a ‘high level of human health protection’ by granting a conditional marketing authorisation to mRNA-technology vaccines in the absence of carcinogenicity and genotoxicity studies.

Top